Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR3 | Q99500 | 2/20 | 0.46 |
| ▸ | SCD | O00767 | 1/20 | 0.45 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.44 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.43 |
| ▸ | CDK2 | P24941 | 1/20 | 0.43 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.43 |
| ▸ | LCK | P06239 | 5/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | FFAR2 | O15552 | 2/20 | 0.41 |
| ▸ | PYGL | P06737 | 1/20 | 0.40 |
| ▸ | GLS | O94925 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21394890 | 1.00 | S1PR3 (0.46) | S1PR3SCDP2RY2CCNE1CDK2 | |
| SCHEMBL21394898 | 0.87 | SCD (0.45) | S1PR3SCDP2RY2CCNE1CDK2 | |
| SCHEMBL29356596 | 0.87 | SCD (0.45) | S1PR3SCDP2RY2CCNE1CDK2 | |
| SCHEMBL21395232 | 0.87 | P2RY2 (0.43) | S1PR3SCDP2RY2CCNE1CDK2 | |
| SCHEMBL21394886 | 0.86 | P2RY2 (0.53) | P2RY2CCNE1CDK2CDK5FFAR2 | |
| SCHEMBL29357987 | 0.86 | CCNE1 (0.47) | SCDP2RY2CCNE1CDK2CDK5 | |
| SCHEMBL21395005 | 0.86 | CCNE1 (0.47) | SCDP2RY2CCNE1CDK2CDK5 | |
| SCHEMBL21395055 | 0.84 | PSEN1 (0.42) | S1PR3SCDP2RY2CCNE1CDK2 | |
| SCHEMBL21394896 | 0.83 | P2RY2 (0.42) | S1PR3SCDP2RY2CCNE1CDK2 | |
| SCHEMBL5026040 | 0.83 | MAPT (0.43) | S1PR3P2RY2CCNE1CDK2CDK5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12180221-B2 | Compounds and uses thereof | JANSSEN PHARMACEUTICA NV (BE) | 2024-12-31 | — | — | US | disclosed |
| US-20230078764-A1 | COMPOUNDS AND USES THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2023-03-16 | — | — | US | disclosed |
| US-20220298168-A1 | COMPOUNDS AND USES THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2022-09-22 | — | — | US | disclosed |
| EP-3941908-A1 | COMPOUNDS AND USES THEREOF | Yumanity Therapeutics, Inc. (US) | 2022-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230078764-A1 | COMPOUNDS AND USES THEREOF | NLN, BDNF, NQO1 | S1PR3 942/4885SCD 3755/4885P2RY2 2029/4885 |
| US-20220298168-A1 | COMPOUNDS AND USES THEREOF | NLN, ACHE, CLN6 | S1PR3 1782/4885SCD 2044/4885P2RY2 998/4885 |
| US-12180221-B2 | Compounds and uses thereof | NLN, ACHE, CLN6 | S1PR3 1782/4885SCD 2044/4885P2RY2 998/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.